# Nannan Chang

> Nannan Chang is a Series A investor at Kaitai Capital backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Kaitai Capital](https://shizune.co/investors/profile/kaitai-capital)
- Total investments: 4
- Last investment: Apr 2021
- Lead investor: 25%
- Last updated: Aug 2026

Nannan Chang is a Series A investor at Kaitai Capital focused on Health Care and Biotechnology. Nannan Chang

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Biopharma | 1 | 25% |
| Therapeutics | 1 | 25% |
| Manufacturing | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PackGene Biotech | PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, wedeliver cost-effective, dependable, and scalable production solutions. |  | Series C | Apr 07, 2021 |  |
| Juncell Therapeutics | Juncell Therapeutics develops innovative therapies and pharmaceutical drugs for tumor and related treatment. |  | Series A | Feb 26, 2021 |  |
| Exegenesis Bio | Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development. |  | Series B | Feb 02, 2021 |  |
| Exegenesis Bio | Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development. |  | Series B | Aug 03, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 2 deals together
- [Decheng Capital](https://shizune.co/investors/profile/decheng-capital) — VC Fund, 2 deals together
- [K2VC](https://shizune.co/investors/profile/k2-vc) — VC Fund, 2 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 2 deals together
- [Boyuan Capital](https://shizune.co/investors/profile/boyuan-capital-4fca) — VC Fund, 1 deal together

## About Kaitai Capital

VC Fund · Hangzhou, China

KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.

5 contacts available at Kaitai Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Huang Zehua | Partner | https://shizune.co/investors/profile/huang-zehua |
| Jin Qi | Managing Partner | https://shizune.co/investors/profile/jin-qi-ef05 |
| Li Xianxian | Managing Partner | https://shizune.co/investors/profile/li-xianxian |
| Nannan Chang | Senior Investment Manager | https://shizune.co/investors/profile/nannan-chang |
| Xian Li | Partner | https://shizune.co/investors/profile/xian-li-67ed |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Nannan Chang invest in?

Nannan Chang invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nannan Chang last invest?

The most recent investment recorded for Nannan Chang closed in Apr 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co